Table 3 Immune-related adverse events (irAE) profile in intention-to-treat (ITT) population
Immune-related adverse events (irAE), in alphabetical order | Guadacitabine (G) and durvalumab (D), ITT population (n = 57) | |
|---|---|---|
Any grade n (%) | G3/4 n (%) | |
Arthralgia | 4 (7) | |
Arthritis | 3 (5) | |
Diarrhea | 13 (22.8) | |
Dyspnea | 16 (28.1) | 2 (3.5) |
Hypothyroidism | 7 (12.3) | |
Lipase increased | 11 (19.3) | 6 (10.5) |
Myalgia | 3 (5) | |
Pneumonitis | 3 (5) | |
Pruritus | 12 (21.1) | 1 (1.8) |
Rash, maculo-papular | 8 (14.0) | |
Increased AST | 3 (5) | |
Increased ALT | 3 (5) | |
